Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

News

‘Twitter Board Views Musk’s Takeover As Unwelcome’ -The Information

The Information

byBenzinga Newsdesk

April 14, 2022

1 minute read

The Information

Acer Therapeutics Q3 EPS $(0.23) Up From $(0.51) YoY

By Bill Haddad

Today, 11:23 PM

Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.23) per share. This is a 54.9 percent increase over losses of $(0.51) per share from the same period last year.

ACER

ChargePoint Holdings Q1 EPS $(0.27) Misses $(0.19) Estimate, Sales $81.60M Beat $75.72M Estimate

By Benzinga Newsdesk

Today, 11:23 PM

ChargePoint Holdings (NYSE:CHPT) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.19) by 42.11 percent. This is a 58.82 percent decrease over losses of $(0.17) per share

CHPT

FDA
News

Fulcrum Therapeutics-Sponsored Study Titled ‘Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets’ Posted To Clinical Trials Website

By Steve Krause

Today, 11:23 PM

https://clinicaltrials.gov/ct2/show/NCT05002231 https://clinicaltrials.gov/ct2/show/NCT05002231

FULC

Alector To Present New Data From Frontotemporal Dementia And Alzheimer’s Disease Programs At The 2021 Alzheimer’s Association International Conference

By Bill Haddad

Today, 11:23 PM

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE

ALEC

‘Twitter Board Views Musk’s Takeover As Unwelcome’ -The Information

Related Posts

Acer Therapeutics Q3 EPS $(0.23) Up From $(0.51) YoY

ChargePoint Holdings Q1 EPS $(0.27) Misses $(0.19) Estimate, Sales $81.60M Beat $75.72M Estimate

Fulcrum Therapeutics-Sponsored Study Titled ‘Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets’ Posted To Clinical Trials Website

Alector To Present New Data From Frontotemporal Dementia And Alzheimer’s Disease Programs At The 2021 Alzheimer’s Association International Conference